Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15016380 | 0.98 | ALDH1A1 (0.53) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL16210731 | 0.94 | ALDH1A1 (0.50) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL7129642 | 0.90 | ALDH1A1 (0.59) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL29564334 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL9496883 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL4145907 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL10723835 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KMT2APKMATMMEN1 | |
| Zinc Ion SCHEMBL15016379 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL5143781 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KMT2APKMATMMEN1 | |
| SCHEMBL6608940 | 0.79 | ALDH1A1 (0.58) | ALDH1A1KMT2APKMATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9796806-B2 | Dioxomolybdenum (VI) complex compounds as catalysts for polyurethane compositions | SIKA TECHNOLOGY AG (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-2791145-B1 | ZINC(II) -COMPLEX-COMPOUNDS AS CATALYSTS FOR POLYURETAHNE-COMPOSITIONS | SIKA TECH AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-9593196-B2 | Zinc(II) complex compounds as catalysts for polyurethane compositions | SIKA TECHNOLOGY AG (CH) | 2017-03-14 | — | — | US | disclosed |
| US-20160326296-A1 | DIOXOMOLYBDENUM (VI) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2016-11-10 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-2791154-B1 | DIOXOMOLYBDENUM(VI) COMPLEXES AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-9422390-B2 | Dioxomolybdenum (VI) complex compounds as catalysts for polyurethane compositions | SIKA TECHNOLOGY AG (CH) | 2016-08-23 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20140329966-A1 | DIOXOMOLYBDENUM (VI) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2014-11-06 | — | — | US | disclosed |
| EP-2791154-A1 | DIOXOMOLYBDENUM (VI) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | Sika Technology AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791145-A1 | ZINC(II) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | Sika Technology AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296427-A1 | ZINC(II) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2014-10-02 | — | — | US | disclosed |
| WO-2013087680-A1 | ZINC(II) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087679-A1 | DIOXOMOLYBDENUM (VI) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | SIKA TECHNOLOGY AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2604613-A1 | Zinc(II) complexes as catalysts for polyurethane compositions | Sika Technology AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604616-A1 | Dioxomolybdenum(VI) complexes as catalysts for polyurethane compositions | Sika Technology AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | ALDH1A1 1539/4885KMT2A 2843/4885PKM 850/4885 |
| US-20160326296-A1 | DIOXOMOLYBDENUM (VI) COMPLEX COMPOUNDS AS CATALYSTS FOR POLYURETHANE COMPOSITIONS | DUOX2, PUF60, DUOX1 | ALDH1A1 2137/4885KMT2A 1839/4885PKM 413/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | ALDH1A1 1539/4885KMT2A 2843/4885PKM 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.